C52R1M

C52R1M is a code name for a drug regimen used as an active comparator in clinical trials evaluating new antihypertensive therapies, specifically AJU-C52, for the treatment of essential hypertension. The exact composition and mechanism of action of C52R1M are not explicitly detailed in public sources; however, it is referenced as a standard or control therapy in phase 3 studies involving patients whose blood pressure is inadequately controlled on other regimens such as C52R1L. These trials are sponsored by Aju Pharm Co., which focuses on innovative therapies for cardiovascular and other diseases[2][3][5][7]. No direct information about the molecular targets or pharmacological class of C52R1M has been published.